Investigating the Additive Effects of Loxacon® Food Supplement Capsules in Patients with Knee Osteoarthritis. A Multicenter, Randomized, Double-Blind, Controlled, Crossover, Follow-Up, Three-Arm Study.

IF 1.7 3区 农林科学 Q4 CHEMISTRY, MEDICINAL
Tamas Bender, P Somogyi, Á Gógl, E Sebők, Gy Gruber, K Hodosi, K Nemes
{"title":"Investigating the Additive Effects of Loxacon<sup>®</sup> Food Supplement Capsules in Patients with Knee Osteoarthritis. A Multicenter, Randomized, Double-Blind, Controlled, Crossover, Follow-Up, Three-Arm Study.","authors":"Tamas Bender, P Somogyi, Á Gógl, E Sebők, Gy Gruber, K Hodosi, K Nemes","doi":"10.1089/jmf.2024.0133","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoarthritis is one of the most common locomotor diseases, with a steadily increasing prevalence and incidence. Loxacon<sup>®</sup> is a food supplement capsule containing vitamins, minerals, and herbal extracts with <i>Boswellia serrata</i> extract and <i>Harpagophytum procumbens</i> extract as its two main active components. The study involved 88 patients at 4 sites. The 88 patients were divided into 3 groups. The first group received physical therapy and Loxacon<sup>®</sup> capsules for 5 weeks, while the second group (30 patients) received physical therapy only for 5 weeks, and the third group (30 patients) received physical therapy and placebo capsules for 5 weeks. After 5 weeks, physical therapy was discontinued in all three groups and all groups continued Loxacon<sup>®</sup> capsules exclusively for an additional 60 days. Physical therapy had been carried out by a standard protocol over 5 weeks. Investigated parameters included Western Ontario and McMaster Universities Arthritis Index (WOMAC) testing, European Quality of Life (EQ-5D-5L) quality of life test and the Range of Motion (ROM). Among the 4 visual analogue scale (VAS) values investigated from WOMAC, significant change was seen for functionality in all three groups; however, the extent of change was twice as large in the physical therapy + Loxacon<sup>®</sup> group at Visit 2 in comparison with the other two groups. In the physical therapy + placebo group, improvement was seen only at the 3rd visit when they were also receiving Loxacon<sup>®</sup> capsules. The most pronounced difference was seen in the minimum clinically important difference index, calculated from the quality of life-VAS, where those taking Loxacon<sup>®</sup> capsules had a chance 3 times as high to obtain clinical improvement versus the other two groups. Our study confirmed that a combination of boswellic acid and harpagosides is beneficial as an additional therapy in knee OA.</p>","PeriodicalId":16440,"journal":{"name":"Journal of medicinal food","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of medicinal food","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1089/jmf.2024.0133","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Osteoarthritis is one of the most common locomotor diseases, with a steadily increasing prevalence and incidence. Loxacon® is a food supplement capsule containing vitamins, minerals, and herbal extracts with Boswellia serrata extract and Harpagophytum procumbens extract as its two main active components. The study involved 88 patients at 4 sites. The 88 patients were divided into 3 groups. The first group received physical therapy and Loxacon® capsules for 5 weeks, while the second group (30 patients) received physical therapy only for 5 weeks, and the third group (30 patients) received physical therapy and placebo capsules for 5 weeks. After 5 weeks, physical therapy was discontinued in all three groups and all groups continued Loxacon® capsules exclusively for an additional 60 days. Physical therapy had been carried out by a standard protocol over 5 weeks. Investigated parameters included Western Ontario and McMaster Universities Arthritis Index (WOMAC) testing, European Quality of Life (EQ-5D-5L) quality of life test and the Range of Motion (ROM). Among the 4 visual analogue scale (VAS) values investigated from WOMAC, significant change was seen for functionality in all three groups; however, the extent of change was twice as large in the physical therapy + Loxacon® group at Visit 2 in comparison with the other two groups. In the physical therapy + placebo group, improvement was seen only at the 3rd visit when they were also receiving Loxacon® capsules. The most pronounced difference was seen in the minimum clinically important difference index, calculated from the quality of life-VAS, where those taking Loxacon® capsules had a chance 3 times as high to obtain clinical improvement versus the other two groups. Our study confirmed that a combination of boswellic acid and harpagosides is beneficial as an additional therapy in knee OA.

调查 Loxacon® 食品补充剂胶囊对膝关节骨关节炎患者的辅助作用。一项多中心、随机、双盲、对照、交叉、随访、三臂研究。
骨关节炎是最常见的运动性疾病之一,其流行率和发病率正在稳步上升。Loxacon® 是一种食品补充剂胶囊,含有维生素、矿物质和草药提取物,其两种主要活性成分是乳香提取物和刺五加提取物。这项研究涉及 4 个地点的 88 名患者。88 名患者被分为 3 组。第一组接受理疗和 Loxacon® 胶囊治疗,为期 5 周;第二组(30 名患者)仅接受理疗,为期 5 周;第三组(30 名患者)接受理疗和安慰剂胶囊治疗,为期 5 周。5 周后,三组患者均停止物理治疗,并继续服用 Loxacon® 胶囊 60 天。物理治疗按照标准方案进行,为期 5 周。调查参数包括西安大略和麦克马斯特大学关节炎指数(WOMAC)测试、欧洲生活质量(EQ-5D-5L)测试和活动范围(ROM)。在对 WOMAC 的 4 个视觉模拟量表(VAS)值进行调查后发现,所有三组患者的功能都发生了显著变化;然而,在第 2 次就诊时,物理治疗 + 乐沙康® 组的变化程度是其他两组的两倍。在物理治疗+安慰剂组中,只有在第 3 次就诊时,即同时服用乐沙康胶囊时,患者的功能才有所改善。最明显的差异体现在最小临床重要差异指数上,根据生活质量-VAS计算,服用乐沙康®胶囊的患者获得临床改善的几率是其他两组的3倍。我们的研究证实,乳香酸和哈巴苷的组合作为膝关节OA的额外疗法是有益的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of medicinal food
Journal of medicinal food 医学-食品科技
CiteScore
4.50
自引率
0.00%
发文量
154
审稿时长
4.5 months
期刊介绍: Journal of Medicinal Food is the only peer-reviewed journal focusing exclusively on the medicinal value and biomedical effects of food materials. International in scope, the Journal advances the knowledge of the development of new food products and dietary supplements targeted at promoting health and the prevention and treatment of disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信